Supplementary Table S1 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors

Chao Kong,Junyi Pu,Qianqian Zhao,Weining Weng,Linjie Ma,Yu Qian,Wenhao Hu,Xun Meng,Tao Meng

DOI: https://doi.org/10.1158/1535-7163.24229621.v1

2023-01-01

Abstract:Supplementary Table S1 shows the amino acid sequences of h6M24, SC16 and hM30

What problem does this paper attempt to address?

Supplementary Fig.S5 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors

Chao Kong,Junyi Pu,Qianqian Zhao,Weining Weng,Linjie Ma,Yu Qian,Wenhao Hu,Xun Meng,Tao Meng

DOI: https://doi.org/10.1158/1535-7163.24229636.v1

2023-01-01

Abstract:Supplementary Fig.S5 shows in vitro and in vivo efficacy of MTX-13
Supplementary Fig.S8 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors

Chao Kong,Junyi Pu,Qianqian Zhao,Weining Weng,Linjie Ma,Yu Qian,Wenhao Hu,Xun Meng,Tao Meng

DOI: https://doi.org/10.1158/1535-7163.24229627

2023-01-01

Abstract:Supplementary Fig.S8 shows MTX-13 prevents metastasis in vivo in an orthotopic colon cancer xenograft model
MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors

Chao Kong,Junyi Pu,Qianqian Zhao,Weining Weng,Linjie Ma,Yu Qian,Wenhao Hu,Xun Meng,Tao Meng

DOI: https://doi.org/10.1158/1535-7163.MCT-23-0164

2023-01-01

Molecular Cancer Therapeutics

Abstract:Protein tyrosine kinase 7 (PTK7) is a Wnt signaling pathway protein implicated in cancer development and metastasis. When using a potent microtubule inhibitor (Aur0101), PTK7-targeting antibody-drug conjugate (ADC), h6M24-vc0101 (PF-06647020/cofetuzumab pelidotin) is efficacious only in limited tumor types with low response rates in a phase I trial. To improve patient response and to expand responding tumor types, we designed MTX-13, a PTK7-targeting ADC consisting of a novel antibody (Ab13) conjugated to eight molecules of topoisomerase I inhibitor exatecan through T1000, a novel self-immolative moiety. MTX-13 exhibited PTK7-specific cell binding, efficient internalization, and exatecan release to cause cytotoxic activity through DNA damage and apoptosis induction, and a strong bystander killing. MTX-13 displayed potent antitumor activities on cell line-derived xenograft and patient-derived xenograft models from a wide range of solid tumors, significantly outperforming h6M24-vc0101. PTK7 was shown to be an actionable target in small cell lung cancer for which MTX-13 showed complete and durable responses. With a consistent overexpression of PTK7 in squamous cell carcinomas derived from diverse anatomic sites, strong potency of MTX-13 in this group of heterogenous tumors suggested a common treatment strategy. Finally, MTX-13 inhibited tumor growth and metastasis in an orthotopic colon cancer xenograft model. MTX-13 displayed a favorable pharmacokinetic and safety profile in monkeys with the highest non-severely toxic dose (HNSTD) of >= 30 mg/kg, significantly higher than 3-5 mg/kg of HNSTD for h6M24-vc0101. The higher therapeutic index of MTX-13 bodes well for its clinical translation with the potential to expand the responding patient population beyond that of current PTK7-targeting ADCs. {Graphical Abstract]
Supplementary Figure 3 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weining Weng,Tao Meng,Junyi Pu,Linjie Ma,Yi Shen,Zhaohui Wang,Rong Pan,Mingqiao Wang,Caiwei Chen,Lijun Wang,Jianjian Zhang,Biao Zhou,Siyuan Shao,Yu Qian,Shuhui Liu,Wenhao Hu,Xun Meng

DOI: https://doi.org/10.1158/1535-7163.24089557

2023-01-01

Abstract:Stability and toxicity in monkey of HER2-targeting ADCs based on T800 and T1000.
Table S1 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma

Jing Shi,Tao Jiao,Qian Guo,Weining Weng,Linjie Ma,Qing Zhang,Lijun Wang,Jianjian Zhang,Caiwei Chen,Yaling Huang,Mingqiao Wang,Rong Pan,Yanfang Tang,Wenhao Hu,Tao Meng,Shu-Hui Liu,Jun Guo,Yan Kong,Xun Meng

DOI: https://doi.org/10.1158/0008-5472.24564639

2023-01-01

Abstract:TK parameters of Non-GLP toxicity studies in monkeys
Supplementary Figure 8 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weining Weng,Tao Meng,Junyi Pu,Linjie Ma,Yi Shen,Zhaohui Wang,Rong Pan,Mingqiao Wang,Caiwei Chen,Lijun Wang,Jianjian Zhang,Biao Zhou,Siyuan Shao,Yu Qian,Shuhui Liu,Wenhao Hu,Xun Meng

DOI: https://doi.org/10.1158/1535-7163.24089539

2023-01-01

Abstract:In vitro efficacy and bystander effect of AMT-562.
Supplementary Figure 12 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weining Weng,Tao Meng,Junyi Pu,Linjie Ma,Yi Shen,Zhaohui Wang,Rong Pan,Mingqiao Wang,Caiwei Chen,Lijun Wang,Jianjian Zhang,Biao Zhou,Siyuan Shao,Yu Qian,Shu-Hui Liu,Wenhao Hu,Xun Meng

DOI: https://doi.org/10.1158/1535-7163.24089572.v1

2023-01-01

Abstract:<p>AMT-562 is more effective as single agent or in combination therapy for colorectal cancer.</p>
Supplementary Table 4 from Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of T(4;14)-Positive Multiple Myeloma

Yunlu Jia,Jianbiao Zhou,Tze King Tan,Tae-Hoon Chung,Yongxia Chen,Jing-Yuan Chooi,Takaomi Sanda,Melissa J. Fullwood,Sinan Xiong,Sabrina H.M. Toh,Kalpnaa Balan,Regina W.J. Wong,Julia S.L. Lim,Enfan Zhang,Zhen Cai,Peng Shen,Wee Joo Chng

DOI: https://doi.org/10.1158/0008-5472.22582472

2023-01-01

Abstract:Supplementary Table 4 shows the sequences of SE fragments inserted into pGL3 vector
Supplementary Figure 11 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weining Weng,Tao Meng,Junyi Pu,Linjie Ma,Yi Shen,Zhaohui Wang,Rong Pan,Mingqiao Wang,Caiwei Chen,Lijun Wang,Jianjian Zhang,Biao Zhou,Siyuan Shao,Yu Qian,Shuhui Liu,Wenhao Hu,Xun Meng

DOI: https://doi.org/10.1158/1535-7163.24089575

2023-01-01

Abstract:In vivo antitumor efficacy of AMT-562 in pancreatic and gastric cancer.
Figure S1-S19 from Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer

Weining Weng,Tao Meng,Qianqian Zhao,Yi Shen,Guoxiang Fu,Jing Shi,Yue Zhang,Zhaohui Wang,Mingqiao Wang,Rong Pan,Linjie Ma,Caiwei Chen,Lijun Wang,Biao Zhou,Hui Zhang,Junyi Pu,Jianjian Zhang,Yi Peter Hu,Guoqiang Hua,Yu Qian,Shu-Hui Liu,Wenhao Hu,Xun Meng

DOI: https://doi.org/10.1158/2159-8290.22553455.v1

2023-01-01

Abstract:Supplementary Figure S1 shows Exatecan cytotoxicity and sensitivity to multidrug resistant genes. Supplementary Figure S2 shows Exatecan and DXd/SN-38 sensitivity to multidrug resistant genes. Supplementary Figure S3 shows Exatecan toxicity in rat. Supplementary Figure S4 shows the design and optimization of T moiety. Supplementary Figure S5 shows physicochemical and functional equivalence of Tras-GGFG-DXd and DS-8201a. Supplementary Figure S6 show physicochemical profile of antibody-exatecan conjugates enabled by T moiety. Supplementary Figure S7 shows additional T moiety-exatecan and belotecan conjugates. Supplementary Figure S8 shows in vitro and in vivo stability of MTX-1000. Supplementary Figure S9 shows cellular dynamics and mechanism of MTX-1000. Supplementary Figure S10 shows colon cancer organoid response to ADCs. Supplementary Figure S11 shows bystander killing effect of MTX-1000, T-DM1 and Tras-GGFG-DXd in coculture conditions in vitro. Supplementary Figure S12 shows hematology and serum chemistry of MTX-1000 in monkey. Supplementary Figure S13 shows T moiety-exatecan ADCs show potent antitumor efficacy and improved therapeutic index. Supplementary Figure S14 shows T moiety-exatecan ADCs show higher antitumor potency in PDX models and better intratumor pharmacodynamic response. Supplementary Figure S15 shows T moiety-exatecan ADCs overcome treatment-resistance due to improved therapeutic index and intratumor pharmacodynamic response. Supplementary Figure S16 shows overcoming MDR resistance by T moiety exatecan ADCs or a combination of MDR inhibitor with DXd/SN-38 ADCs. Supplementary Figure S17 shows Exatecan/MTX-1000 and PARP/ATR inhibitor synergize in colon cancer cells. Supplementary Figure S18 shows a patient-derived xenograft (PDX) model with EGFR triple mutation. Supplementary Figure S19 shows MTX-1000 induces immunological cell death and enhances antitumor immunity of anti-PD-1.
Supplementary Table S1 from METTL1-Mediated M<sup>7</sup>g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zhengde Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.22433516

2023-01-01

Abstract:This file shows the antibodies used in the study.
Supplemental Table S3 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Jing Zhang,Sun Min Lim,Mi Ra Yu,Cheng Chen,Jia Wang,Wenqian Wang,Haopeng Rui,Jingtao Lu,Shun Lu,Tony Mok,Zhi Jian Chen,Byoung Chul Cho

DOI: https://doi.org/10.1158/2159-8290.26934995.v1

2024-01-01

Abstract:Supplemental Table S3 summarizing the anti-tumor activity of D3S-001 in CDX, PDX or PDO xenograft models
Table S1-S7 from Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer

Weining Weng,Tao Meng,Qianqian Zhao,Yi Shen,Guoxiang Fu,Jing Shi,Yue Zhang,Zhaohui Wang,Mingqiao Wang,Rong Pan,Linjie Ma,Caiwei Chen,Lijun Wang,Biao Zhou,Hui Zhang,Junyi Pu,Jianjian Zhang,Yi Peter Hu,Guoqiang Hua,Yu Qian,Shu-Hui Liu,Wenhao Hu,Xun Meng

DOI: https://doi.org/10.1158/2159-8290.22553449

2023-01-01

Abstract:Supplementary Table S1 shows cytotoxicity of exatecan compared to DXd. Supplementary Table S2 shows selected hematologic parameters and biochemical parameters from the repeat-dose administration of exatecan mesylate studies in rats. Supplementary Table S3 shows in vitro ADC stability study of total antibody, ADC and free payload. Supplementary Table S4 shows pharmacokinetic parameters of total antibody, ADC and free payload. Supplementary Table S5 shows ADC (T: T-1000-e; D: DS-8201a) internalization rate on cell lines with different HER2 expression level. Supplementary Table S6 shows correlation of exatecan release and target expression. Supplementary Table S7 shows In vitro cytotoxicicity of HER-targeting MTX-1000, TROP2 targeting MTX-132 and HER3-targeting Patritumab-T1000-exatecan and their counterpart DXd-ADC.
Supplementary Table S8 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers

Wei Zhou,Peng Fang,Dongan Yu,Hongyuan Ren,Meng You,Long Yin,Fei Mei,Huikai Zhu,Zhenzhen Wang,Hui Xu,Yuxia Cao,Xiaowei Sun,Xiaohong Xu,Jianjun Bi,Jin Wang,Lanping Ma,Xin Wang,Lin Chen,Yongliang Zhang,Xiaowei Cen,Xi Zhu,Liguang Lou,Datao Liu,Xiaoding Tan,Jinliang Yang,Tao Meng,Jingkang Shen

DOI: https://doi.org/10.1158/1535-7163.23814323.v1

2023-01-01

Abstract:Binding affinity and kinetics based on Bio Layer Interferometry
Supplementary Figures S1-S6 from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity Against Tumor Cells and Tumor Vasculature

Alberto Visintin,Kelly Knowlton,Edyta Tyminski,Chi‐Iou Lin,Xunhua Zheng,Kimberly Marquette,Srishti Jain,Lioudmila Tchistiakova,Dan Li,Christopher J. O’Donnell,Andreas Maderna,Xiaomei Cao,Robert R. Dunn,William Snyder,Anson K. Abraham,Mauricio Leal,Shoba Shetty,Anthony Barry,Leigh Zawel,Anthony J. Coyle,Harold F. Dvorak,Shou-Ching Jaminet

DOI: https://doi.org/10.1158/1535-7163.22505884

2023-01-01

Abstract:Supplementary Figures S1-S6. Supplementary Figure S1. Liquid chromatography electrospray ionization tandem mass spectrometry analysis; Supplementary Figure S2. TM4SF1 expression in human breast and colon cancers; Supplementary Figure S3A. Clearance of anti-TM4SF1 antibody from HUVEC surface; Supplementary Figure S3B. Uptake of anti-TM4SF1 antibody in HUVEC; Supplementary Figure S4A. NSCLC killing by anti-TM4SF1 ADC; Supplementary Figure S4B. Tumor cell killing by anti-TM4SF1 ADC; Supplementary Figure S5. Expression level of TM4SF1 and other endothelial cell markers in tumor xenografts; Supplementary Figure S6. Clearance of anti-TM4SF1 ADCs; tolerance in mice.
Supplementary Figure 13 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weining Weng,Tao Meng,Junyi Pu,Linjie Ma,Yi Shen,Zhaohui Wang,Rong Pan,Mingqiao Wang,Caiwei Chen,Lijun Wang,Jianjian Zhang,Biao Zhou,Siyuan Shao,Yu Qian,Shu-Hui Liu,Wenhao Hu,Xun Meng

DOI: https://doi.org/10.1158/1535-7163.24089566.v1

2023-01-01

Abstract:HER3 expression in NSCLC and clinical trial status of U3-1402.
Supplemental Table S4 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Jing Zhang,Sun Min Lim,Mi Ra Yu,Cheng Chen,Jia Wang,Wenqian Wang,Haopeng Rui,Jingtao Lu,Shun Lu,Tony Mok,Zhi Jian Chen,Byoung Chul Cho

DOI: https://doi.org/10.1158/2159-8290.26934992

2024-01-01

Abstract:Supplemental Table S4 summarizing RNAseq and WES analysis of acquired resistant clones from MIA PaCa-2 xenograft model.
Supplementary Data from Antimalarial Drug Pyrimethamine Plays a Dual Role in Antitumor Proliferation and Metastasis Through Targeting DHFR and TP

Huijuan Liu,Yuan Qin,Denghui Zhai,Qiang Zhang,Jie Gu,Yuanhao Tang,Jiahuan Yang,Kun Li,Lan Yang,Shuang Chen,Weilong Zhong,Jun Meng,Yanrong Liu,Tao Sun,Cheng Yang

DOI: https://doi.org/10.1158/1535-7163.22506459

2023-01-01

Abstract:Figure S1 Chemical structure of Pyrimethamine and Methotrexate; Figure S2 Changes of E-cadherin and vimentin expression in A549 cells treated with Pyr or MTX (immunofluorescence assay); Figure S3 Changes in E-cadherin and vimentin expression in A549 cells treated with Pyr or MTX (Western blot assay); Figure S4 Effect of Pyr and MTX on the expression of EMT markers in LLC xenograft tumor tissues (Western blot assay); Figure S5 Molecular docking results for TP inhibitors (TPI, 5-iodouracil [5UIR], and 5-fluorouracil [5UFR]) and TP; Figure S6 Interaction between Pyr and TP verified by Thermal shift assay (TSA).
Supplemental Table S5 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Jing Zhang,Sun Min Lim,Mi Ra Yu,Cheng Chen,Jia Wang,Wenqian Wang,Haopeng Rui,Jingtao Lu,Shun Lu,Tony Mok,Zhi Jian Chen,Byoung Chul Cho

DOI: https://doi.org/10.1158/2159-8290.26934989

2024-01-01

Abstract:Supplemental Table S5 summarizing tumor growth inhibition analysis of the AMG510-R-xMIA PaCa-2 (clone 2) xenograft model

Supplementary Table S1 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors

Supplementary Fig.S5 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors

Supplementary Fig.S8 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors

MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors

Supplementary Figure 3 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Table S1 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma

Supplementary Figure 8 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Supplementary Figure 12 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Supplementary Table 4 from Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of T(4;14)-Positive Multiple Myeloma

Supplementary Figure 11 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Figure S1-S19 from Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer

Supplementary Table S1 from METTL1-Mediated M&lt;sup&gt;7&lt;/sup&gt;g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplemental Table S3 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Table S1-S7 from Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer

Supplementary Table S8 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers

Supplementary Figures S1-S6 from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity Against Tumor Cells and Tumor Vasculature

Supplementary Figure 13 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Supplemental Table S4 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Supplementary Data from Antimalarial Drug Pyrimethamine Plays a Dual Role in Antitumor Proliferation and Metastasis Through Targeting DHFR and TP

Supplemental Table S5 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Supplementary Table S1 from METTL1-Mediated M<sup>7</sup>g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma